iRhythm Signs $100 Million Accelerated Share Buyback
By Katherine Hamilton
iRhythm entered an accelerated share buyback agreement with JPMorgan Chase.
The agreement is for $100 million in shares, as part of its previously announced $200 million share buyback authorization, the digital healthcare company said Tuesday.
Under the terms of the deal, iRhythm will make an initial payment of $100 million to JPMorgan and receive an initial delivery of shares representing about 80% of the total number of shares expected to be repurchased.
iRhythm plans to fund the buyback with existing cash and cash equivalents.
The total number of shares repurchased will be determined based on the volume-weighted average price of iRhythm's stock during the term of the buyback.
Final settlement of the accelerated buyback is expected to happen no later than the first quarter of 2027. Once completed, iRhythm will have about $100 million left in its buyback authorization program.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
November 17, 2026 17:11 ET (22:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

